Trial Profile

DAREON-7: A Phase I, Open-label, Dose Escalation and Expansion Trial to Investigate Safety and Tolerability of BI 764532 Intravenous Infusions in Combination With Standard of Care (Platinum and Etoposide) in First-line Treatment of Patients With Neuroendocrine Carcinomas (NEC)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Sep 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Etoposide (Primary) ; Obrixtamig (Primary)
Indications Neuroendocrine carcinoma
Focus Adverse reactions
Acronyms DAREON™-7
Sponsors Boehringer Ingelheim; Boehringer Ingelheim GmbH International

29 Jun 2026 This trial has been completed in Germany.
23 Jun 2026 Planned End Date changed from 25 Apr 2027 to 31 Dec 2027.
23 Jun 2026 Planned primary completion date changed from 9 Feb 2027 to 9 Oct 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com